5-Azacytidine (Azacytidine; Vidaza) in Chronic Lymphocytic Leukemia
- First Posted Date
- 2006-12-19
- Last Posted Date
- 2015-06-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 9
- Registration Number
- NCT00413478
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
Phase 2
Recruiting
- Conditions
- Hairy Cell LeukemiaRecurrent Hairy Cell Leukemia
- Interventions
- First Posted Date
- 2006-12-18
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 150
- Registration Number
- NCT00412594
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Smoking Status and Body Image in Oral Cancer Patients
Completed
- Conditions
- Oral Cavity Cancer
- Interventions
- Behavioral: QuestionnaireBehavioral: Interview
- First Posted Date
- 2006-12-18
- Last Posted Date
- 2016-01-29
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 75
- Registration Number
- NCT00412490
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Clofarabine and Cyclophosphamide Combination in Acute Lymphoblastic Leukemia Patients
Phase 1
Completed
- Conditions
- Burkitt's LymphomaLymphoblastic LymphomaAcute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2006-12-18
- Last Posted Date
- 2013-03-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 51
- Registration Number
- NCT00412243
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Thalidomide and Temozolomide or Camptothecin-11 (CPT-11) in Patients With Gliomas
Phase 2
Completed
- Conditions
- Glioblastoma MultiformeGlioma
- Interventions
- First Posted Date
- 2006-12-18
- Last Posted Date
- 2012-02-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 78
- Registration Number
- NCT00412542
- Locations
- 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States
Palonosetron for Prevention of Biochemotherapy Induced Nausea and Vomiting
- First Posted Date
- 2006-12-18
- Last Posted Date
- 2012-05-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT00412425
- Locations
- 🇺🇸
U.T. M.D. Anderson Cancer Center, Houston, Texas, United States
Lenalidomide and Dacarbazine (DTIC) in Patients With Metastatic Melanoma
- First Posted Date
- 2006-12-18
- Last Posted Date
- 2016-04-29
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 28
- Registration Number
- NCT00412581
- Locations
- 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States
BATTLE Program: Sorafenib in Patients With NSCLC
- First Posted Date
- 2006-12-14
- Last Posted Date
- 2016-02-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 105
- Registration Number
- NCT00411671
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
BATTLE Program: Tarceva and Targretin in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2006-12-14
- Last Posted Date
- 2020-01-29
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 37
- Registration Number
- NCT00411632
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Phase I-II for Patients With Recurrent or Refractory Non-small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2006-12-14
- Last Posted Date
- 2012-02-08
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT00411593
© Copyright 2025. All Rights Reserved by MedPath